SoftWave Tissue Regeneration Technology (TRT) and StemWave are both part of the growing field of shockwave therapies. While they share a common purpose, the two devices differ in design, FDA status, research support, and day-to-day clinical use. This guide compares the SoftWave TRT Gold Series and the StemWave Modus-F to help patients and providers understand which shockwave therapy may be the better fit.
Both SoftWave and StemWave treatments are generally well tolerated. Patients often describe SoftWave as a dull soreness that eases quickly, with many reporting relief that lasts two to three years before symptoms return. StemWave is more often described as a gradual buildup of pressure during treatment, which most patients tolerate without significant discomfort.
Both devices fall into the same general cost range — $150–$250 per session — and are not covered by insurance. Clinics often help patients use HSA or FSA funds for payment.
SoftWave is the only unfocused shockwave device with multiple FDA clearances. It is backed by two decades of clinical use, over $25 million in research and development, and more than 240 peer-reviewed studies. Leading institutions such as Harvard, UCLA, and Cleveland Clinic rely on SoftWave, and it is trusted by professional sports organizations including the MLB, NFL, NBA, and UFC.
SoftWave is used across specialties, including orthopedics, podiatry, physical therapy, sports medicine, and urology. Its ability to deliver energy both wide and deep makes it effective for conditions such as plantar fasciitis, Achilles tendon injuries, arthritis pain, scar tissue, and post-surgical stiffness. Patients who have not responded to conventional treatments often benefit from SoftWave’s broader reach.
SoftWave’s patented parabolic reflector creates a broad-focused wave that delivers both a primary and secondary energy field. This allows for deeper, wider coverage and more predictable outcomes. Its clear applicator membrane ensures gas bubbles, which can block energy transfer are visible and easily managed during treatment.
SoftWave provides certified on-site training, conducted with real patient sessions that generate revenue for the clinic while educating staff. This approach removes the need for off-site travel and downtime, helping practices integrate SoftWave into their daily operations without disruption.
With over 1,400 clinics in North America, SoftWave offers one of the largest shockwave provider networks. The online Provider Search tool makes it simple for patients to locate nearby clinics, increasing patient confidence and clinic visibility.
SoftWave has earned recognition from key opinion leaders in orthopedics, wound care, and urology. Its adoption by leading medical centers and use by national sports teams to treat elite athletes demonstrates its credibility and proven results. With 47 patents, additional patents pending, and 30+ active clinical trials, SoftWave continues to lead innovation in shockwave therapy.